Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

AIDS

Volumn 17, Issue 8, 2003, Pages 1151-1156

  Louie, Michael ^a   Hogan, Christine ^a   Hurley, Arlene ^a   Simon, Viviana ^a   Chung, Chris ^a   Padte, Neal ^a   Lamy, Patrick ^b   Flaherty, John ^b   Coakley, Dion ^b   Di Mascio, Michele ^c   Perelson, Alan S ^c   Markowitz, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GILEAD SCIENCES   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Antiviral activity; Tenofovir DF

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MALE; MEASUREMENT; MODEL; MONOTHERAPY; PLASMA; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CHRONIC DISEASE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0037530011     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00006     Document Type: Article

References (24)

1. Perelson AS, Essunger P, Ho DD. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 1997, 11:S17-S24.
2. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002, 16:1257-1263.
3. Staszewski S, Gallant J, Pozniak A, Suleiman J, Dejesus E, Koenig E, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. In XIV International Conference on AIDS. Barcelona, July 2002 [abstract LbOr17].
4. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
5. van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, et al. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antirnicrob Agents Chemother 1996, 40:2586-2591.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.
8. Nelson PW, Mittler JE, Perelson AS. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters. J Acquir Immune Defic Syndr 2001, 26:405-412.
9. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001, 45:1438-1443.
10. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001, 358:1760-1765.
11. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354:1782-1785.
12. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999, 4:87-94.
13. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002, 16:1227-1235.
14. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001, 6:115-126.
15. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
16. Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, et al. A Phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with > 300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retro-viruses 2002, 18:699-704.
17. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
18. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998, 177:1533-1540.
19. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
20. Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998, 12: F203-F209.
21. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001, 45:2733-2739.
22. Little S, Holte S, Routy JP, Paar ES, Markowitz M, Collier A, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
23. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002, 16:1511-1519.
24. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.